How to treat a new eye disease in the UK
The National Ophthalmology Consultative Group (NOCG) has advised the UK Government that a trial of the use of Ocular Lidocaine (EL) is now necessary to treat the first cases of the new eye disorder known as Sjogren’s syndrome.
We believe that we have the potential to make a difference to the lives of people with Sjgens syndrome, and that it is important that this trial is conducted as quickly as possible.” “
In the UK, EL is a commonly used anti-inflammatory drug and has been used for decades to treat inflammatory conditions such as diabetes and psoriasis, but there are concerns that it may cause an increased risk of the rare condition known as SCID-19.”
We believe that we have the potential to make a difference to the lives of people with Sjgens syndrome, and that it is important that this trial is conducted as quickly as possible.
“We will be doing further research to ensure that this treatment works for everyone.” “
The results of the trial will allow us to determine whether EL has the potential for treatment of Sjgs and if so, whether it is effective for the first time,” Dr Barden added.
“We will be doing further research to ensure that this treatment works for everyone.”
Dr Bessie Barden said:”We have the opportunity to help many people, including those who have previously had a life-threatening disease, to lead a healthier and more productive life.”
By using EL, we are able to protect patients from the complications of SdGs and prevent the disease from becoming chronic and ultimately fatal.
“Sjgns are among the most complex and costly conditions of the modern age, and we need to be sure that we are taking the right steps to prevent it from becoming even more complicated and expensive.”
Dr Barden also said that while EL is used in Europe, it is currently not approved in the United Kingdom.
“While the UK does have a trial under way in Oxford University, it will not be conducted until our UK trials are approved.”
However, it’s important to remember that there are other drugs which we are currently developing which are currently being tested in the U.K., which we will be able to test in the coming weeks.
“However, in the Sjoggens syndrome case we have been able to demonstrate that EL can be used to stop progression of the disease.” “
There are several types of EL available in the medical market and they are generally used to treat conditions such for instance diabetes, psorias, arthritis and asthma,” Dr Darryl Gannon, from the British Ophthalmic Society, said.
“However, in the Sjoggens syndrome case we have been able to demonstrate that EL can be used to stop progression of the disease.”
Dr Gannon added that the treatment could be particularly beneficial for people with conditions such an inflammatory skin disorder, who have an increased need for the drug.
The National Ocular Consultative Council (NocC) was set up in 1996 to advise the UK government on the safety of drugs, and is currently responsible for making recommendations on all drugs approved in Britain.
Dr Bessies Barden agreed that EL had the potential “to be very important”, adding that the drug had been used in clinical trials in the US, China, France, Germany, the U, Italy, Spain, Japan, Australia and the UK.
“This is a very exciting development in terms of the potential use of EL in Sjogs and that the use is now being approved in this country.”
The key is to get EL approved here in the British NHS, which will allow the drug to be administered to the patients who need it most, so that they have a safe and effective treatment.
“”In the future, we hope that EL will be used in combination with other medications for the treatment of the condition, and also to treat patients with autoimmune diseases and inflammatory conditions.
“There is currently no cure for SjGs, which can affect a person’s vision, nerve and muscles.
More to come…”
It’s been well documented that the growth of SJGs can lead to significant side effects, and for this reason, we believe that it’s critical that patients have the appropriate treatment,” Dr Gannon said.
More to come…